Effects of monomethylfumarate on human granulocytes.

Monomethylfumarate (MMF) is the most active metabolite of the new antipsoriasis drug Fumaderm. Because granulocytes play an important role in the pathophysiology of psoriasis, the effects of this drug on the functional activities of these cells were investigated. MMF stimulated polarization and elastase release, and enhanced the intracellular killing of bacteria by granulocytes. This compound suppressed the formyl-Met-Nle-Phe (FMLP)-stimulated respiratory burst in these cells. MMF and dimethylfumarate but not its stereoisomer dimethylmaleate, fumaric acid, or dimethylmalate stimulated polarization of and elastase release by granulocytes, indicating that methylated fumarate derivatives interact with granulocytes in a specific fashion. MMF did not affect the binding of formyl-Nle-Leu-Phe-Nle-Tyr-Lys-fluorescein isothiocyanate to the FMLP receptor on granulocytes. This compound induced an increase in the intracellular Ca++ ([Ca++]i) and cyclic adenosine monophsphate concentration. The agonistic effects of MMF on granulocytes are thought to be mediated by the rise in the [Ca++]i and the antagonistic effects by the increase in the cyclic adenosine monophosphate concentration. These effects of MMF on granulocytes may in part explain the beneficial action of methylated fumarate derivatives on psoriatic skin lesions.

[1]  P. Nibbering,et al.  A new competition binding assay for determination of the cAMP content of human leukocytes. , 1991, Biochemical and biophysical research communications.

[2]  J. Hermans,et al.  Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. , 1990, Journal of the American Academy of Dermatology.

[3]  L. Sklar,et al.  Coupling of antagonistic signalling pathways in modulation of neutrophil function , 1989, Journal of cellular biochemistry.

[4]  S. Denis,et al.  The activity of one soluble component of the cell-free NADPH:O2 oxidoreductase of human neutrophils depends on guanosine 5'-O-(3-thio)triphosphate. , 1990, The Journal of biological chemistry.

[5]  J. Shields,et al.  Neutrophil leucocyte chemotaxis: a simplified assay for measuring polarizing responses to chemotactic factors. , 1985, Journal of immunological methods.

[6]  M. Greaves,et al.  NEUTROPHIL POLYMORPHONUCLEARS, MEDIATORS AND THE PATHOGENESIS OF PSORIASIS , 1983, The British journal of dermatology.

[7]  B. Babior,et al.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. , 1973, The Journal of clinical investigation.

[8]  T. Henriksen.  Energy transfer and radioprotection in biological systems. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[9]  F. Maxfield,et al.  Transient increases in cytosolic free calcium appear to be required for the migration of adherent human neutrophils [published erratum appears in J Cell Biol 1990 Mar;110(3):861] , 1990, The Journal of cell biology.

[10]  P. Wilkinson,et al.  Effects of phorbol esters on shape and locomotion of human blood lymphocytes. , 1988, Journal of cell science.

[11]  P. Nibbering,et al.  Interferon‐γ‐activated human granulocytes kill ingested Mycobacterium fortuitum more efficiently than normal granulocytes , 1990, European journal of immunology.

[12]  C. Nieboer,et al.  Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. , 1989, Journal of the American Academy of Dermatology.

[13]  R. van Furth,et al.  A reaction vessel for the measurement of oxygen consumption by small numbers of cells in suspension. , 1986, Journal of immunological methods.

[14]  Paul,et al.  Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3. , 1991, Blood.

[15]  F. Di Virgilio,et al.  Cyclic AMP inhibition of phosphoinositide turnover in human neutrophils. , 1986, Biochimica et biophysica acta.

[16]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[17]  L A Sklar,et al.  The dynamics of ligand-receptor interactions. Real-time analyses of association, dissociation, and internalization of an N-formyl peptide and its receptors on the human neutrophil. , 1984, The Journal of biological chemistry.

[18]  M. Baggiolini,et al.  Mechanism of neutrophil activation by NAF, a novel monocyte‐derived peptide agonist , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  J. O'flaherty,et al.  Tumor necrosis factor-alpha regulates expression of receptors for formyl-methionyl-leucyl-phenylalanine, leukotriene B4, and platelet-activating factor. Dissociation from priming in human polymorphonuclear neutrophils. , 1991, Journal of immunology.

[20]  J. Barker,et al.  Pathophysiology of psoriasis. , 1977, Annual review of medicine.

[21]  R. Snyderman,et al.  Calcium influx requirement for human neutrophil chemotaxis: inhibition by lanthanum chloride. , 1976, Science.

[22]  James T. Elder,et al.  Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. , 1991, The American journal of pathology.

[23]  J. Schröder,et al.  Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. , 1986, The Journal of investigative dermatology.

[24]  K. Matsushima,et al.  Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor. , 1989, Immunology.

[25]  B. Dewald,et al.  A novel neutrophil-activating factor produced by human mononuclear phagocytes , 1988, The Journal of experimental medicine.